Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease
Reuters
Published Jun 12, 2023 01:23AM ET
Updated Jun 12, 2023 07:56PM ET
By Ludwig Burger
(Reuters) -Novartis said it has agreed to acquire U.S. biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment.
Seattle-based Chinook's shareholders will receive $3.2 billion, or $40 per share, in cash under the agreed deal, plus a contingent value right worth up to $300 million, depending on certain regulatory achievements, Novartis said on Monday.
The upfront payment represents a premium of 66.7% to Chinook's Friday closing price. Chinook's shares were at $40.1 in premarket trading on Monday.
Novartis CEO Vas Narasimhan is eager to raise the prospect of future blockbuster drugs after leading a push to slash costs and reshape the Swiss drugmaker to focus on fewer therapeutic areas and the most promising geographic markets.
Chinook, whose shares closed at $23.99 on Friday, has a leading compound designed to treat IgA Nephrophathy, or IgAN, a rare disease that can lead to kidney failure in young adults which has attracted a range of developers and is already the target of drug candidate developed by Novartis.
Narasimham has previously said he would look primarily at deal targets worth less than $5 billion.
The transaction is expected to close in the second half of 2023, Novartis said in a statement.
Chinook expects to see the pivotal readout in the fourth quarter of this year of a clinical trial in the third and last stage of development of oral drug candidate atrasentan to treat IgAN.
Chinook is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a Phase 3 trial in the third quarter of 2023.
Narasimhan scored a major win this year when breast cancer drug Kisqali, one of two new drugs crucial to the group's sales growth, was shown to help a wider patient group in a study.
The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease.
Companies working on potential IgAN treatments include Roche, Vera Therapeutics, Ionis, Omeros (NASDAQ:OMER) and unlisted HI-Bio.
IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. No targeted treatment options are available, Novartis said.
In the United States, IgAN affects up to 21 people per million per year, with a higher rate among Asian populations. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added.
Novartis is set to become more dependent on its drug development fortunes as it plans to spin off its generic drugs division Sandoz in the second half of 2023.
Get The News You Want
Chinook shares slumped, but quickly recovered, last month when short-seller Muddy Waters (NYSE:WAT) said it was betting on the stock to fall because atrasentan was unlikely to reach market maturity.
Muddy Waters said last week it remained short on Chinook.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.